Meeting
2023 ASCO Annual Meeting
Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.
Authors
Andrew David Knight
University of Pittsburgh Medical Center, Pittsburgh, PA
Andrew David Knight , Lilit Karapetyan , Sabrina Bruno , Hassan Mohammed Abushukair , Na Bo , Hong Wang , Cindy Sander , John M. M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9580)
DOI
10.1200/JCO.2023.41.16_suppl.9580
Abstract #
9580
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
First Author: Michael B. Atkins
Poster
2024 ASCO Breakthrough
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
First Author: Vincent T. Ma
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2023 ASCO Annual Meeting
Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study.
First Author: Hildur Helgadottir